Drug Profile
Research programme: oral factor Xa inhibitors - Roche/TeaRx
Latest Information Update: 23 Feb 2023
Price :
$50
*
At a glance
- Originator Roche
- Developer Roche; TeaRx
- Class
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Deep vein thrombosis; Pulmonary embolism; Stroke
Most Recent Events
- 23 Feb 2023 Discontinued - Preclinical for Deep vein thrombosis (Prevention) in Russia (PO)
- 23 Feb 2023 Discontinued - Preclinical for Pulmonary embolism (Prevention) in Russia (PO)
- 23 Feb 2023 Discontinued - Preclinical for Stroke (Prevention) in Russia (PO)